CSF2 and neoplasm: In agreement, mice harboring a selective deficiency of PPARγ in Lysozyme-2-expressing cells (e.g., macrophages) showed impaired tumor rejection after treatment with GM-CSF-secreting and irradiated tumor cell-based vaccine (GVAX) [237].